newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - IMMUNOCORE HOLDINGS PLC

  • Financial Performance:

    • Immunocore disclosed having just over $900 million in cash on the balance sheet, indicating strong liquidity.
    • ChemTrack penetration has reached 70%+ in all major markets, including nearly 70% in the U.S., establishing it as the standard of care.
    • Growth for ChemTrack is expected to moderate as it enters the mature phase of its product life cycle, shifting from rapid launch growth to sustained access expansion.
    • No specific revenue figures, profit margins, or debt levels were explicitly detailed in the transcript provided.
  • Guidance and Future Outlook:

    • Tebiam Study (Metastatic Melanoma): Registration data expected in Q2 2027; management suggests a later date may indicate longer patient survival (slower event accrual) rather than clinical issues.
    • PRISM-MEL Study (First-line Melanoma): Enrollment expected to complete in 2027, with PFS endpoint data anticipated in 2028.
    • HIV Program: Updated data on higher dose escalation (up to 1200 micrograms) to be presented at a medical conference in 2026.
    • Autoimmune (Type 1 Diabetes): First patient dosed in Q3 2025; Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) data to provide evidence of target engagement and C-peptide preservation.
    • Long-term Goals: Plan to develop oncology assets in-house while seeking partners for inflection points in autoimmune and infectious disease sectors where internal commercial footprints are less established.
  • Business Segments and Product Lines:

    • ChemTrack (Uveal Melanoma):
      • Duration of therapy stabilized at ~14 months in real-world settings, exceeding clinical trial metrics (10-11 months).
      • Growth drivers include expanding into community settings in the U.S. and new market launches/duration increases in International (OUS).
      • Safety profile is manageable with low single-digit adverse events post-initial doses and no cumulative toxicities.
    • ChemTrack + Bernanfusp (Uveal Melanoma Combination):
      • Phase 1 data showed significant improvement over monotherapy: ORR 29% vs. 11%, PFS 8.1 months vs. 3.4 months, Duration of Response 24 months, and 2-year OS 70% vs. 45%.
      • Moving toward Phase 2/3 development based on biological rationale (PRAME negative prognostic) and superior efficacy.
    • Tebiam Study (Metastatic Melanoma):
      • Phase 3 randomized study in HLA-positive second-line patients; control arm includes PD-1 retreatment (approx. 33%), BRAF retreatment (20-25%), or chemo/palliative care.
      • Historical Phase 2 data suggested 16-18 months OS in the drug arm vs. 10-11 months in control.
    • HIV Program:
      • Aiming for a functional cure; high-dose testing completed with no dose-limiting toxicities observed.
    • Innate Immunology (INI) / Autoimmune:
      • PD-1 agonist bispecific in development for Type 1 Diabetes (pre-proinsulin targeting + PD-1 agonism) and potentially Atopic Dermatitis.
      • Capital-efficient design targeting C-peptide preservation as a surrogate for insulin production.
  • Market and Competitive Landscape:

    • Uveal Melanoma: ChemTrack is insulated from upcoming oral competitors targeting HLA-negative patients; ChemTrack specifically targets the HLA-positive population.
    • Metastatic Melanoma: The Tebiam study controls for a difficult landscape with no standard of care in this line (post-PD-1/CTLA-4 failure); no newer immunotherapies are approved in the primary enrollment regions (Europe), ensuring a realistic control arm.
    • Platform Capability: Management emphasizes the modularity of the bispecific platform, successfully applying oncology learnings to infectious disease and autoimmune indications.
  • Risks and Challenges:

    • Trial Timing: The delay of the Tebiam data readout from late 2025 to Q2 2027 introduces execution risk, though management views the delay as potentially positive regarding survival duration.
    • Competition: While ChemTrack is insulated in HLA-positive Uveal, the pipeline faces the inherent risks of late-stage clinical trial failure in complex oncology and autoimmune diseases.
    • Market Saturation: ChemTrack growth is naturally moderating as penetration peaks, requiring reliance on new launches (OUS) and combination therapies for future revenue.
  • Management Commentary and Tone:

    • Tone is confident and data-driven, particularly regarding the "stunning" efficacy of the ChemTrack + Bernanfusp combination in Uveal Melanoma.
    • Management expresses strong conviction in the biological consistency between Uveal and Cutaneous melanoma (GP100 expression) to support the Tebiam study.
    • Executive leadership demonstrates a disciplined capital allocation strategy, prioritizing efficient capital use in immunology/autoimmune to reach value inflection points before seeking partnerships.
  • Analyst Questions and Answers:

    • ChemTrack Growth: Confirmed growth is now driven by community access (US) and new market launches/duration (OUS); therapy duration is stable at 14 months.
    • Competitor Filing: Reiterated that upcoming oral competitors target HLA-negative patients, leaving ChemTrack's core HLA-positive revenue stream largely insulated.
    • Tebiam Control Arm: Detailed the likely mix of the control arm (PD-1 retreatment, BRAF, chemo), estimating an OS of 10-11 months, making a statistically significant OS benefit a clear commercial differentiator.
    • Partnership Strategy: Confirmed intention to partner in autoimmune and infectious disease post-inflection point to maximize value, while retaining oncology assets in-house.
    • HIV Data Delay: Explained the delay in HIV data disclosure is due to dose escalation to 1200 micrograms to further optimize and demonstrate antiviral activity, with safety remaining robust.
  • Other Key Points:

    • The 5-year overall survival data for ChemTrack in Uveal Melanoma showed a doubling of survival, with nearly half of those patients treated with ChemTrack alone, reinforcing the "start with ChemTrack" messaging.
    • The Type 1 Diabetes program utilizes a tissue-specific approach to target beta cells specifically, aiming to preserve endogenous insulin production.
    • The company remains "well capitalized" with nearly $1 billion in cash, reducing immediate funding pressure for the pipeline.
Company
IMMUNOCORE HOLDINGS PLC
Keywords
IMMUNOCORE HOLDINGS PLC